NEWS

Compass Therapeutics Announces First Patient Dosed in Combination Trial with KEYTRUDA	12.01.22
Ovation Appoints Chief Revenue Officer and Head of Product Marketing	11.10.22
Compass Therapeutics Announces $80M Private Placement	11.02.22
Ankyra Appoints Joseph Elassal as Chief Medical Officer	10.17.22
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 Combination	10.11.22
Ovation Launches Ovation Research Network	07.12.22

Page 1 of 12